



Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 09/963,827
Applicant: Sullenger *et al.*
Filed: September 26, 2001
TC/A.AU.: 1635
Examiner: Sean McGarry

Confirmation No.: 1175

Docket No.: 10815.105005 RBI REG001
Customer No.: 20786
Title: RNA Aptamers and Methods for Identifying the Same

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the accompanying Form PTO/SB/08A, "Information Disclosure Statement by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited reference is enclosed with the exception of the U.S. patents. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

A check for \$180.00 is enclosed because this paper is being submitted after the mailing of a first Office Action on the merits but before the mailing of a final Office Action, as under 37 C.F.R. § 1.97(c). However, should the Commissioner determine that other fees are due, he is hereby authorized to charge such fees and to credit any overpayment to Deposit Account No. 11-0980.

10/18/2006 RHEBRAHT 00000016 09963827

01 FC:1806

180.00 OP

Dated: October 11, 2006
King & Spalding LLP
1180 Peachtree Street, 34th Floor
Atlanta, GA 30309-3521
Office: (404) 572-4600/ Fax: (404) 572-5134

Respectfully submitted,


Brent R. Bellows, Ph.D., Esq.
Reg. No. 54,709

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 11, 2006.

F. Russell Denton

4274746_1.DOC



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	09/963,827
Filing Date	September 26, 2001
First Named Inventor	Sullenger <i>et al.</i>
Group Art Unit	1635
Examiner Name	Sean R. McGarry
Attorney Docket Number	10815.105005

4278616 1.DOC1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages/Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	5,648,214	A	Nieuwlandt, <i>et al.</i>	07-15-1997	
	AB	5,760,202	A	Cook <i>et al.</i>	06-02-1998	
	AC	5,843,653	A	Gold <i>et al.</i>	12-01-1998	
	AD	6,001,820	A	Hirsh <i>et al.</i>	12-14-1999	
	AE	6,005,087	A	Cook <i>et al.</i>	12-21-1999	
	AF	6,011,020	A	Gold <i>et al.</i>	01-04-2000	
	AG	6,083,696	A	Biesecker <i>et al.</i>	07-04-2000	
	AH	6,110,900	A	Gold <i>et al.</i>	08-29-2000	
	AI	6,117,557	A	Massie, II, <i>et al.</i>	09-12-2000	
	AJ	6,316,198	B1	Skouv <i>et al.</i>	11-13-2001	
	AK	2003-0083294	A1	Sullenger <i>et al.</i>	05-01-2003	
	AL	2006-0040881	A1	Rusconi	02-23-2006	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages- Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ² (if known)				
	AM	EP	0,593,901	A2	Hoechst AG	04-27-1994		
	AN	WO	02/026932	A2	Duke University	04-04-2002		
	AO	WO	02/096926	A1	Duke University	12-05-2002		
	AP	WO	03/093422	A2	Schering	11-13-2003		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AQ	BEIGELMAN, L., <i>et al.</i> , "Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance," <i>J. Biol. Chem.</i> , 270(43):25702-25708 (October 25, 1995).	
	AR	BLACK, A.R., and AZIZKHAN-CLIFFORD, J., "Regulation of E2F: a family of transcription factors involved in proliferation control," <i>Gene</i> , 237(2):281-302 (September 17, 1999).	
	AS	CHASE, J.W., and WILLIAMS, K.R., "Single-stranded DNA binding proteins required for DNA replication," <i>Annu. Rev. Biochem.</i> , 55:103-136 (1986).	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/963,827
				Filing Date	September 26, 2001
				First Named Inventor	Sullenger <i>et al.</i>
				Group Art Unit	1635
				Examiner Name	Sean R. McGarry
Sheet	2	of	3	Attorney Docket Number	10815.105005

4278616 1.DOC 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	DALE, R.M., <i>et al.</i> , "Direct covalent mercuration of nucleotides and polynucleotides," <i>Biochemistry</i> , 14(11):2447-2457 (June 3, 1975).	
	BB	DAVIES, J., <i>et al.</i> , Chap. 8, p. 185, in <i>RNA World</i> (Cold Spring Harbor Laboratory Press; eds. Gestlaad and Atkins; 1993).	
	BC	DeANDA, A. Jr., <i>et al.</i> , "Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass," <i>Ann. Thorac. Surg.</i> , 58(2):344-350 (August 1994).	
	BD	EICHORN, G.L., <i>et al.</i> , "Interaction of metal ions with polynucleotides and related compounds. XII. The relative effect of various metal ions on DNA helicity," <i>J. Am. Chem. Soc.</i> , 90(26):7323-7328 (December 18, 1968).	
	BE	FEUERSTEIN, G.Z., <i>et al.</i> , "Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 19(10):2554-2562 (October 1999).	
	BF	GOOD, P.D., <i>et al.</i> , "Expression of small, therapeutic RNAs in human cell nuclei," <i>Gene Ther.</i> , 4(1):45-54 (January 1997).	
	BG	GRIFFIN, L.C., <i>et al.</i> , "In vivo anticoagulant properties of a novel nucleotide-based thrombin inhibitor and demonstration of regional anticoagulation in extracorporeal circuits," <i>Blood</i> , 81(12):3271-3276 (June 15, 1993).	
	BH	HARBOUR, J.W., and DEAN, D.C., "The Rb/E2F pathway: expanding roles and emerging paradigms," <i>Genes Dev.</i> , 14(19):2393-2409 (October 1, 2000).	
	BI	HELIN, K., and ED, H., "The retinoblastoma protein as a transcriptional repressor," <i>Trends Cell Biol.</i> , 3(2):43-46 (February 1993).	
	BJ	HUNTER, T., "Braking the cycle," <i>Cell</i> , 75(5):839-841 (December 3, 1993).	
	BK	ISHIZAKI, J., <i>et al.</i> , "Inhibition of cell proliferation by an RNA ligand that selectively blocks E2F function," <i>Nature Med.</i> , 2(12):1386-1389 (December 1996).	
	BL	LA THANGUE, N.B., "DRTF1/E2F: an expanding family of heterodimeric transcription factors implicated in cell-cycle control," <i>Trends Biochem. Sci.</i> , 19(3):108-114 (March 1994).	
	BM	LEE, S.W., <i>et al.</i> , "Isolation of a nuclease-resistant decoy RNA that can protect human acetylcholine receptors from myasthenic antibodies," <i>Nature Biotechnol.</i> , 15(1):41-45 (January 1997).	
	BN	LIPPARD, S.J., <i>et al.</i> , "Platinum complexes: probes of polynucleotide structure and antitumor drugs," <i>Acc. Chem. Res.</i> , 11:211-217 (1978).	
	BO	MANN, K.G., <i>et al.</i> , "Surface-dependent reactions of the vitamin K-dependent enzyme complexes," <i>Blood</i> , 76(1):1-16 (July 1, 1990).	
	BP	NEVINS, J.R., "E2F: a link between the Rb tumor suppressor protein and viral oncoproteins," <i>Science</i> , 258(5081):424-429 (October 16, 1992).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **3** of **3****Complete if Known**

Application Number	09/963,827
Filing Date	September 26, 2001
First Named Inventor	Sullenger <i>et al.</i>
Group Art Unit	1635
Examiner Name	Sean R. McGarry
Attorney Docket Number	10815.105005

4278616 1.DOC 1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	CA	PIEKEN, W.A., <i>et al.</i> , "Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes," <i>Science</i> , 253(5017):314-317 (July 19, 1991).	
	CB	RUSCONI, C.P., <i>et al.</i> , "Blocking the initiation of coagulation by RNA aptamers to factor VIIa," <i>Thrombosis and Haemostasis</i> , 84(5):841-848 (November 2000).	
	CC	SHERR, C.J., "Mammalian G1 cyclins," <i>Cell</i> , 73(6):1059-1065 (June 18, 1993).	
	CD	SHERR, C.J., and ROBERTS, J.M., "Inhibitors of mammalian G1 cyclin-dependent kinases," <i>Genes Dev.</i> , 9(10):1149-1163 (May 15, 1995).	
	CE	SULLENGER, B.A., <i>et al.</i> , "Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication," <i>Cell</i> , 63(3):601-608 (November 2, 1990).	
	CF	TUCKER, C.E., <i>et al.</i> , "Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys," <i>J. Chromatog. B, Biomed. Sci. Appl.</i> , 732(1):203-212 (September 10, 1999).	
	CG	WEINBERG, R.A., "The retinoblastoma protein and cell cycle control," <i>Cell</i> , 81(3):323-330 (May 5, 1995).	
	CH	WHITE, R.R., <i>et al.</i> , "Developing aptamers into therapeutics," <i>J. Clin. Invest.</i> , 106(8):929-934 (October 2000).	
	CI	WILLIS, M.C., <i>et al.</i> , "Liposome-anchored vascular endothelial growth factor aptamers," <i>Bioconjug. Chem.</i> , 9(5):573-582, (September-October 1998).	
	CJ	WILLIS, M.C., <i>et al.</i> , "Liposome-anchored vascular endothelial growth factor aptamers," <i>Bioconjug. Chem.</i> , 9(5):633 (September-October 1998) [Erratum, Collins, B., corrected to Collins, B.D.].	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.